WO2010012244A1 - 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 - Google Patents
乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 Download PDFInfo
- Publication number
- WO2010012244A1 WO2010012244A1 PCT/CN2009/073049 CN2009073049W WO2010012244A1 WO 2010012244 A1 WO2010012244 A1 WO 2010012244A1 CN 2009073049 W CN2009073049 W CN 2009073049W WO 2010012244 A1 WO2010012244 A1 WO 2010012244A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hbv
- nucleic acid
- small interfering
- interfering nucleic
- small
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the small nucleic acid of the hepatitis B virus gene interferes with the target site sequence and
- the present invention relates to a small nucleic acid interference target site sequence and a small interfering nucleic acid and a composition and application thereof for a hepatitis B virus gene, and more particularly to a small nucleic acid interference target site sequence of a hepatitis B virus gene, A small nucleic acid for inhibiting expression of a hepatitis B virus gene, and a pharmaceutical composition containing the small interfering nucleic acid and the use of the small interfering nucleic acid for preparing a pharmaceutical composition for preventing and/or treating hepatitis B. Background technique
- Hepatitis B is referred to as hepatitis B and is an infectious disease caused by hepatitis B virus (HBV).
- HBV hepatitis B virus
- WHO World Health Organization
- HBV hepatitis B virus
- the methods for treating hepatitis B mainly include antiviral replication, improving immune function, protecting liver cells, promoting liver cell regeneration, and comprehensive treatments such as traditional Chinese medicine treatment, basic treatment and psychotherapy.
- the globally recognized drugs for the prevention and treatment of hepatitis B can be divided into two major categories: interferon and nucleoside analogues. Interferon has been used as a treatment for hepatitis B for a long time, and its terminal response rate is only 30%. Even after combination with other antiviral drugs or increasing dose, the terminal response rate is only 50%, and the drug is discontinued. After reducing or reducing the number of injections, it is easy to relapse and the adverse reactions are significantly increased. In addition, long-term use induces interferon antibodies and loses efficacy.
- Nucleoside analogs have a fast onset of action, but the terminal response rate is not high, and nucleoside analogs only inhibit the virus in the liver cytoplasm and have no effect on CCC-DNA in the nucleus of hepatocytes, requiring long-term maintenance.
- the main problem facing long-term medication is the drug resistance caused by virus mutation, and it is also prone to virus rebound and high recurrence rate after drug withdrawal. More serious is the apparent deterioration of liver function and even death after a few patients have stopped taking the drug. It is undoubtedly the most ideal treatment for hepatitis B to inhibit the production and replication of HBV at the genetic level to reduce viral metabolism and infect liver cells.
- a first object of the present invention is to provide a small nucleic acid interference target site sequence of a hepatitis B virus gene.
- a second object of the present invention is to provide a small interfering nucleic acid for inhibiting the expression of a hepatitis B virus gene.
- a third object of the present invention is to provide a pharmaceutical composition comprising the small interfering nucleic acid.
- a fourth object of the present invention is to provide use of the small interfering nucleic acid for the preparation of a pharmaceutical composition for preventing and/or treating hepatitis B.
- RNA interference Small nucleic acid interference can also be called RNA interference (RN A interference, RNAi), which is composed of double-stranded RNA.
- RNA interference technology also known as knock-down or gene silencing
- PTGS post-transcriptional gene silencing
- Hamilton and Baulcombe detected RNA fragments of 21-25 nucleotides in length in plants with RNA interference. These RNA fragments proved to be required for RNA interference, called small interfering (siRNA, Small interfering).
- siRNA small interfering nucleic acid
- RNA-induced silencing complex forms an RNA-induced silencing complex (RISC) with cell-derived related enzymes and proteins.
- RISC RNA-induced silencing complex
- the sense strand in the small interfering nucleic acid (siRNA) is excluded from the complex, the antisense strand directs the RISC to bind to the corresponding site of the target mRNA, and then the target mRNA is degraded by ribonuclease III in the complex. Thereby the expression of the target gene is turned off.
- RNAi has developed rapidly in the field of infectious disease and malignant gene therapy as a highly efficient sequence-specific gene knockout technique. Selection of a sequence in the viral genome that is not homologous to the human genome as an inhibitory sequence can prevent viral side replication while avoiding toxic side effects on normal tissues.
- Small interfering nucleic acids inhibit the expression of genes more than 1000 times more efficiently than the currently used methods (antibody or antisense oligodeoxynucleotide), and are safe, specific, and highly efficient. Therefore, the use of small interfering nucleic acid (siRNA) drugs for the treatment of hepatitis B has the advantage that conventional drugs cannot match.
- Hepatitis B virus is a hepadna DNA
- the genome is about 3.2 kb in length and is a partially double-stranded circular DNA; the hepatitis B virus genome contains four open reading frames (ORF, S gene region, C gene region, P gene region, and X gene region).
- the S gene region includes the S gene, the pre-S1 gene and the pre-S2 gene, which encode the S protein, the M protein, and the L protein, respectively; wherein the S protein and the M protein are closely related to the hepatic, genetic, and transcriptional activation of the hepatitis B virus. Related.
- the C gene region includes the pre-C gene and the C gene, which respectively encode the nucleocapsid proteins HBeAg and HBcAg, which are important components of the core part of the hepatitis B virus and are the main body of viral replication.
- the P gene region includes the P gene, which encodes the P protein.
- the P protein contains 816 amino acids and has four functional domains, including DNA polymerase with reverse transcriptase activity and RNase H, which participate in the whole process of HBV replication.
- the X gene region includes the X gene, which is the smallest open reading frame in the HBV viral genome. It is located at 1374-1838 bp in the HBV genome and has a full length of about 435-462 bp. It encodes a protein of 154 amino acids in length. Direct or Intermittent interaction affects the replication and proliferation of the virus itself, and can affect the apoptosis and carcinogenesis of infected cells in the host cell.
- the present invention provides a small nucleic acid interference target site sequence of a hepatitis B virus gene, wherein the interference target site sequence comprises one of SEQ ID Nos: 2-11 a nucleotide sequence, and the length of the interfering target site sequence is 15-27 nucleotides.
- the present invention also provides a small interfering nucleic acid, wherein the small interfering nucleic acid is a double-stranded RNA molecule, including a sense strand and an antisense strand, and the sense strand and the antisense strand
- the length is 15-27 nucleotides, and the 3' end of each of the sense strand and the antisense strand are two consecutive deoxythymidylates, and the sense strand and the antisense strand are removed from the 3' end.
- nucleotides other than the continuous deoxythymidylate complement each other to form a double strand, wherein the antisense strand of the small interfering nucleic acid can complement the base of the small nucleic acid interference target site provided by the present invention to inhibit hepatitis B Expression of viral genes.
- the present invention also provides a pharmaceutical composition for preventing and/or treating hepatitis B, wherein the pharmaceutical composition contains the small interfering nucleic acid provided by the present invention as an active ingredient.
- the present invention also provides the use of the small interfering nucleic acid described in the preparation of a pharmaceutical composition for preventing and/or treating hepatitis B.
- the present invention reduces the viral load by specifically inhibiting the expression of one or several genes in the S gene region, the C gene region, the P gene region and the X gene region in the hepatitis B virus genome, and invading at the gene level
- the body's hepatitis B virus works to prevent and treat hepatitis B disease.
- the small interference nucleic acid provided by the present invention has high inhibitory activity against hepatitis B virus gene expression and can effectively prevent and/or treat hepatitis B.
- the present invention provides a small nucleic acid interference target site sequence of a hepatitis B virus gene, wherein the interference target site sequence comprises the nucleotide sequence shown as one of SEQ ID Nos: 2-11, preferably comprising SEQ ID No 2.
- the nucleotide sequence of SEQ ID No: 4, SEQ ID No: 8, or SEQ ID No: 10 and the length of the interfering target site sequence is 15-27 nucleotides, preferably 19-21 nucleotides.
- the small nucleic acid interference target site refers to a nucleotide sequence in the mRNA sequence of the gene that is complementary to the antisense strand of the small interfering nucleic acid in the process of inhibiting gene expression using a small interfering nucleic acid.
- sequence of the interfering target site is as shown in one of SEQ ID Nos: 12-21, and further preferably, the sequence of the interfering target site is SEQ ID No: 12, SEQ ID No. : 14, SEQ ID No: 18, or SEQ ID No: 20.
- the present invention also provides a small interfering nucleic acid (siRNA), wherein the small interfering nucleic acid is a double-stranded RNA molecule, including a sense strand and an antisense strand, and the sense strand and the antisense strand are 15-27 in length Nucleotide, wherein each of the sense strand and the antisense strand has two consecutive deoxythymidylates, and the sense strand and the antisense strand are separated from the two consecutive deoxythymidylates at the 3' end.
- siRNA small interfering nucleic acid
- the other nucleotides are complementary to form a double strand, wherein the antisense strand of the small interfering nucleic acid is capable of complementing the base of the small nucleic acid interference target site provided by the present invention to inhibit the expression of the hepatitis B virus gene.
- the small interfering nucleic acid provided by the present invention is a double-stranded molecule including a sense strand and an antisense strand, and the sense strand and the antisense strand are respectively 15-27 nucleotides in length; preferably, the sense strand and the opposite strand
- the sense strands are 19-21 nucleotides in length, respectively.
- the small interfering nucleic acid has HBV-X1, HBV-X2, HBV-X3, HBV-X4, HBV-PI, HBV-P2, HBV-PSK HBV-PS2, HBV- Nucleotide sequence indicated by CI or HBV-C2, or with HBV-X1, HBV-X2, HBV-X3, HBV-X4, HBV-P1 HBV-P2, HBV-PS1, HBV-PS2, HBV-Cl a nucleotide sequence obtained by chemically modifying a nucleotide sequence represented by HBV-C2, wherein
- HBV-X1 justice chain 5,- CGACCGACCUUGAGGCAUAdTdT-3'
- Antisense strand 5,- UAUGCCUCAAGGUCGGUCGdTdT-3';
- HBV-X2 justice chain 5,- CCUUGAGGCAUACUUCAAAdTdT-3 '
- Antisense strand 5,- UUUGAAGUAUGCCUCAAGGdTdT-3 ';
- HBV-X3 justice chain 5,- GCGGGACGUCCUUUGUUUAdTdT-3 '
- Antisense strand 5'- UAAACAAAGGACGUCCCGCdTdT-3';
- HBV-X4 justice chain 5'- CUAGGAGGCUGUAGGCAUAdTdT-3 '
- Antisense strand 5'- UAUGCCUACAGCCUCCUAGdTdT-3';
- HBV-P1 justice chain: 5'- GGAACAAGAUCUACAGCAUdTdT-3'
- Antisense chain 5,- AUGCUGUAGAUCUUGUUCCdTdT-3';
- HBV-P2 justice chain: 5,- G A AAGU AUGUC A ACG A AUUdTdT -3,
- Antisense chain 5,- A AUUCGUUG AC AU ACUUUCdTdT -3 ';
- HBV-PS1 justice chain 5' - GAUCCAGCCUUCAGAGCAAdTdT-3'
- Antisense strand 5,- UUGCUCUGAAGGCUGGAUCdTdT-3';
- HBV-PS2 justice chain 5' - CGUCAAUCUUCUCGAGGAUdTdT-3'
- Antisense strand 5,- AUCCUCGAGAAGAUUGACGdTdT-3';
- HBV-C1 justice chain: 5,- GGGUGUUAAUUUGGAAGAUdTdT-3'
- Antisense strand 5,- AUCUUCCAAAUUAACACCCdTdT-3';
- HBV-C2 justice chain: 5,- GGAAACUACUGUUGUUAGAdTdT-3 '
- Antisense strand 5,- UCUAACAACAGUAGUUUCCdTdT-3'.
- the small interfering nucleic acid has a nucleotide sequence represented by HBV-X1, HBV-X3, HBV-PS1 or HBV-Cl.
- the chemical modification is at least one of the following modifications:
- the chemical modification is well known to those skilled in the art, and the modification of the phosphodiester bond refers to a phosphodiester bond.
- the oxygen in the modification is modified, including the phosphorothioate modification, as shown in Formula 1; and the boron phosphate phosphate modification, as shown in Formula 2. Both modifications stabilize the structure of small interfering nucleic acids, maintaining high specificity and high affinity for base pairing.
- the ribose modification refers to a modification of 2'-OH in a nucleotide pentose, gp, which introduces a certain substituent at the hydroxyl position of the ribose, for example, a 2'-fluoro modification, as shown in Formula 3; - oxymethyl modification, as shown in Formula 4; 2'-oxyethylene methoxy modification, as shown in Formula 5; 2,4'-dinitrophenol modification, as shown in Formula 6; LNA), as shown in Formula 7; 2'-amino modification, as shown in Formula 8; 2'-deoxy modification, as shown in Formula 9.
- the base modification refers to modification of a nucleotide base, for example, 5'-bromouracil modification, as shown in Formula 10; 5'-iodouracil modification, As shown in Formula 11; N-methyluracil modification, as shown in Formula 12; 2,6-diaminopurine modification, as shown in Formula 13.
- the modification enhances the ability of the modified small interfering nucleic acid to resist nuclease hydrolysis in the cell.
- a lipophilic group such as cholesterol may be introduced at the end of the sense strand of the small interfering nucleic acid based on the above modification, and the lipophilic group includes a covalent bond and a small interfering nucleic acid. , such as the introduction of cholesterol, lipoprotein, vitamin E, etc. at the end, in order to facilitate the passage of cell membranes composed of lipid bilayers The intracellular mRNA acts.
- small interfering nucleic acids can also be modified by non-covalent bonds, such as hydrophobic bonds or ionic bonds to bind phospholipid molecules, polypeptides, cationic polymers, etc. to increase stability and biological activity.
- Methods of preparing small interfering nucleic acids include the design of small interfering nucleic acid sequences and the preparation of small interfering nucleic acids.
- the design of the small interfering nucleic acid refers to the selection of a relatively conserved hepatitis B virus strain (Genbank accession number U95551) as a template. For the conserved regions of the X, P, S, and C genes of hepatitis B virus, a 19 bp nucleotide sequence was selected to design a corresponding small interfering nucleic acid.
- the conserved regions of the X, P, S, and C genes are 1376-1820 bp, 2309 bp to 1625 bp, 2848-837 bp, and 1816 bp to 2454 bp, respectively, in the HBV genome (Genbank accession number U95551).
- the small interfering nucleic acid sequences designed for the X, P, S, and C genes are designed according to the following principles:
- a nucleotide sequence of 19 bp in length was selected from the genomes of 1376-1820 bp, 2309 bp to 1625 bp, 2848-837 bp, and 1816 bp to 2454 bp of the hepatitis B virus U95551 strain genome.
- the selection of the 19 bp nucleotide sequence mainly refers to the following principles: (1) GC content is between 35-55 %, (2) avoiding in the sequence of repeat sequences or low complexity, (3) avoiding more than 4 a contiguous base sequence, (4) avoiding single nucleotide polymorphism sites, (5) avoiding within the 50-100 bp region of the reading frame start and stop passwords, in addition to Analyze the composition and thermodynamic properties of the nucleotide sequence.
- the candidate small interfering nucleic acid target sites are homologously aligned with the human gene sequence, and sequences with great sequence homology (16 or more bases) with other genes are excluded to ensure candidate small interference.
- the nucleic acid target site does not inhibit other non-related genes, but only has a specific inhibitory effect on the hepatitis B virus gene.
- the 3' end of the 19 bp nucleotide sequence thus obtained is added with two deoxythymidine nucleotides as the sense strand of the small interfering nucleic acid sequence, and two at the 3' end of the complementary sequence of the 19 bp nucleotide sequence.
- One deoxythymidine nucleotide acts as the antisense strand of the small interfering nucleic acid sequence.
- the preparation method of the small interfering nucleic acid is known to those skilled in the art.
- the small interfering nucleic acid can be obtained by chemical synthesis or by expression of a plasmid and/or a viral vector.
- the synthesis of the small interfering nucleic acid sequence can be carried out by chemical synthesis or by a biotechnology company specialized in nucleic acid synthesis, such as commissioning by Shanghai GenePharma.
- the chemical synthesis method includes the following four processes: (1) synthesis of oligoribonucleotides; (2) deprotection; (3) purification separation; (4) desalting.
- the specific steps of chemical synthesis of small interfering nucleic acids having a nucleotide sequence represented by HBV-X1 are as follows: (1) Synthesis of oligoribonucleotides: synthesis of oligoribonucleotides is in automated DNA/ The RNA synthesizer (for example, Applied Biosystems EXPEDITE 8909) is carried out, and the corresponding nucleotides are linked one by one according to the order of the nucleotide sequences shown by HBV-X1. Since the small interfering nucleic acid is composed of a section of 19 oligoribonucleotides and 2 deoxythymidylates.
- the starting material is a solid phase-linked 5'-0-p-dimethoxy-thymidine.
- the specific synthesis of each cycle can be divided into four steps.
- the first step is to immobilize the thymidine.
- the protecting group at the 5' position is eluted by the action of trichloroacetic acid;
- the second step is 5,-0-p-dimethoxytrityl group under the action of the active catalyst S-ethyltetrazole.
- the thymidine phosphoramidite is coupled to the thymidine which has been deprotected to form the dithymidine phosphite triester.
- the coupling time and the number of couplings are completed according to the procedure provided by the instrument manufacturer; the third step is to couple the The dithymidine phosphite triester is oxidized to dithymidine phosphate triester under the action of 0.05 M iodine water; the fourth step is acetylation, and a small amount of unreacted reactive groups on the solid phase (for example, hydroxyl and amine groups) An ester or amide is formed under the action of acetic anhydride to achieve a blocking effect to reduce the production of overall by-products, which is repeated until the synthesis of all nucleic acid sequences is completed.
- the crude product of small interfering nucleic acid was dissolved in 2 ml of aqueous ammonium acetate solution, and then separated by high-pressure liquid chromatography by reaction C18, and the main product of small interfering nucleic acid was collected by gradient elution (eluent A: 0.1 M acetic acid).
- eluent B 20% of 0.1 M ammonium acetate and 80% acetonitrile
- the purified small interfering nucleic acid is dialyzed to remove the salt, and then the small interfering nucleic acid solution is subjected to filter sterilization and dry crystallization.
- the oligoribonucleotide of the sense strand and the antisense strand are then annealed to form a stable double-stranded small interfering nucleic acid by mixing the oligoribonucleotide of the sense strand and the antisense strand in 1-2 ml.
- small interfering nucleic acids can also be obtained by expression of plasmids and/or viral vectors, resulting in a shRNA having a hairpin structure of 50-90 nucleotides in length.
- the structure of shRNA is:
- the ends are cleavage sites (such as BamH? and EcoR?), and the middle is a loop sequence (such as GAAGCTTG), which is inserted into the vector digested with the corresponding endonuclease by cloning technology and integrated into the chromosome. , can stably express small interfering nucleic acids.
- the present invention also provides a pharmaceutical composition for preventing and/or treating hepatitis B disease, wherein the pharmaceutical composition contains the small interfering nucleic acid provided by the present invention as an active ingredient.
- the pharmaceutical composition may be an injection.
- the injection solution contains a pharmaceutically acceptable carrier and the small interfering nucleic acid provided by the present invention
- the content of the small interfering nucleic acid and the pharmaceutically acceptable carrier may vary within a wide range, and preferably, the pharmaceutically acceptable carrier is contained in an amount of 100 to 10,000,000 parts by weight relative to 100 parts by weight of the small interfering nucleic acid. .
- the pharmaceutically acceptable carrier is not particularly limited, and may be a phosphate buffer having a pH of 4.0 to 9.0 and a trishydroxymethylaminoguanidine hydrochloride buffer having a pH of 7.5 to 8.5.
- the injection solution may further contain a protective agent and/or an osmotic pressure adjusting agent;
- the protective agent is contained in an amount of 0.01 to 30% by weight based on the injection solution, and the protective agent is selected from the group consisting of inositol One or more of sorbitol and sucrose;
- the osmotic pressure adjusting agent is present in an amount such that the osmotic pressure of the injection is 200-700 milliosmoles per kilogram, and the osmotic pressure adjusting agent is sodium chloride and/or Or potassium chloride.
- the amount to be administered may be a dose conventionally used in the art, and the dose may be determined according to various parameters, particularly depending on the age, body weight and severity of the condition of the patient to be treated.
- the invention also provides the use of said small interfering nucleic acid for the preparation of a pharmaceutical composition for the prevention and/or treatment of hepatitis B.
- Example 1 The present invention will be further illustrated by the following examples, and the reagents and culture media used in the present invention are commercially available unless otherwise specified.
- Example 1 The reagents and culture media used in the present invention are commercially available unless otherwise specified.
- the hepatitis B virus genome (Genbank accession number U95551) (SEQ ID NO. 1) with a relatively conserved sequence was selected as a template.
- a 19 bp nucleotide sequence was selected to design a small interfering nucleic acid.
- a nucleotide sequence of 19 bp in length was selected from the genome of hepatitis B virus U95551 strain in the range of 1376-1820 bp, 2309 bp to 1625 bp, and 2848-837 bp 1816 bp to 2454 bp.
- the selection of the 19 bp nucleotide sequence mainly refers to the following principles: (1) GC content is between 35-55 %, (2) avoiding in the sequence of repeat sequences or low complexity, (3) avoiding more than 4 a contiguous base sequence, (4) avoiding single nucleotide polymorphism sites, (5) avoiding within the 50-100 bp region of the reading frame start and stop passwords, in addition to Analyze the composition and thermodynamic properties of the nucleotide sequence.
- the candidate small interfering nucleic acid target sites are homologously aligned with the human gene sequence, and sequences with great sequence homology (16 or more bases) with other genes are excluded to ensure candidate small interference.
- the nucleic acid target site does not inhibit other non-related genes, but only has a specific inhibitory effect on the hepatitis B virus gene.
- the 3' end of the 19 bp nucleotide sequence thus obtained is added with two deoxythymidine nucleotides as the sense strand of the small interfering nucleic acid sequence, and two at the 3' end of the complementary sequence of the 19 bp nucleotide sequence.
- One deoxythymidine nucleotide acts as the antisense strand of the small interfering nucleic acid sequence.
- the target site sequence challenged by the small interfering nucleic acid designed in this embodiment includes the nucleotide sequence shown in one of SEQ ID Nos: 2-11, and the specific small nucleic acid interference target site sequence is SEQ ID Nos: 12 One of -21 (19 nucleotides in length).
- the designed small interfering nucleic acid was chemically synthesized by GenePharma, and the small interfering nucleic acids HBV-XI to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2 and HBV-C1 were obtained. HBV-C2, their nucleotide sequences are shown in Table 1. Table 1
- the range of attack refers to the corresponding position of the small interfering nucleic acid in SEQ ID: NO.
- HepG2.2.15 cells were seeded at a density of 1 ⁇ 10 5 cells/well in 24-well cell culture plates using DMEM complete medium containing 10% fetal bovine serum, 2 mM L-glutamine, 380 ug/ml G418 (from Beijing) University People's Hospital), cultured in an incubator with a temperature of 37 ° C and a C02 content of 5%, passaged and replaced every 72 hours Fresh medium.
- the cells were digested with 0.25% trypsin, counted, and then seeded into 24-well plates at a concentration of lxlO 5 cells/ml, 1000 ⁇ l per well.
- the small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2, and HBV-C1 to HBV-C2 obtained in Example 1 were obtained using Invitrogen's LipofectamineTM 2000 liposome. Transfection was performed separately without adding small interfering nucleic acids as a blank control.
- the specific steps are as follows: Dissolve the small interfering nucleic acid in RNase-free sterile water to prepare a small interfering nucleic acid solution with a concentration of 2 (mol/L. Aspirate the supernatant from each well, add 0.5 ml of OptiMEM I low. Serum medium (Invitrogen, 31985-062). Dilute 3 ⁇ 1 small interfering nucleic acid solution (20 ⁇ 1/ ⁇ in 50 ⁇ 1 Opti-MEM I low serum medium (Invitrogen, 31985-062), respectively.
- LipofectamineTM The 2000 liposome was diluted in 50 ⁇ l Opti-MEM I low serum medium (Invitrogen, 31985 ⁇ 62), and then the above two solutions were incubated at room temperature for 5 minutes, mixed, and the mixed solution was allowed to stand at room temperature for 20 minutes, and then ⁇ The mixed solution was added to the 24-well plate inoculated with cells. The final concentration of the small interfering nucleic acid was 100 ⁇ . The cells were cultured at 37 ° C for 4 hours, and then 1 ml of 10% fetal bovine serum and 2 mM L-glutamine were added. 100 U/ml penicillin, 10 ( ⁇ g/ml streptomycin in MEM complete medium, and then incubated at 37 ° C for an additional 48 hours.
- the specific steps are as follows: Using lml Tri Z0 l (GIBCOL) to lyse HepG2.2.15 cells transfected with small interfering nucleic acid and continuously extracting hepatitis B virus, and extracting total RNA, the specific steps of extracting total RNA are: after transfection The cells were cultured in an incubator at 37 ° C and a C0 2 content of 5% for 48 hours, and then the cells were collected by centrifugation and washed once with pre-cooled 2 ml of PBS; the composition of the PBS was: NaCl 137 mmol/L, KC1 2.7mmol/L, Na 2 HP0 4 4.3mmol/L, KH 2 P0 4 1.4mmol/L; add 1ml Trizol per well, let stand for 5 minutes at room temperature, lyse the cells; transfer the lysate to 1.5ml EP tube; 200 ⁇ l chloroform, shaking vigorously by hand for 15 seconds, room temperature for 3 minutes; 14000 r
- RNA-free Two units of DNase I (RNase-free) ( TakaRa) were added to the above-mentioned RNA-dissolved DEPC water, and allowed to stand at 37 ° C for 30 minutes to remove residual DNA in the total RNA. After treatment with DNase I, the total RNA was purified by Invitrogen's PureLink Micro-to-Midi Total RNA Purification Kit. The specific steps for purification were as follows: Add 20 ⁇ l of 70% ethanol to the total RNA, shake well and mix well. The mixture was transferred to a purification column, centrifuged at 12,000 rpm for 15 seconds at room temperature, the filtrate was discarded, and 700 ⁇ l of Wash Buffer I (TakaRa) was added.
- TakaRa Wash Buffer I
- the reverse transcription reaction is carried out on the total RNA obtained after purification.
- the reverse transcriptase used is Promega's M-MLV reverse transcriptase.
- the specific steps of the reverse transcription reaction are: the total RNA after purification of lug and Oligo dT of lul (0.5ug) was mixed in a test tube, the total volume was made up to 16.25 ⁇ 1 with DEPC water, and the test tube was heated.
- the heating conditions included a heating temperature of 70 ° C and a heating time of 5 minutes; The mixture was rapidly cooled to 0 ° C, and buffer (5 x MLV buffer 5 ⁇ l, 10 mM Dntp 1.25 ⁇ l, RNasin 0.5 ⁇ l, M-MLV 1 ⁇ 1) was added thereto, and incubated at 42 ° C for 1 hour to obtain cDNA.
- the obtained cDNA was used as a template for a PCR reaction, and a Real-time PCR reaction was carried out.
- the Real-time PCR reaction system is: ⁇ 1 (1 ⁇ 2 0 17.5 ⁇ 1, 10mM Dntp 0.5 ⁇ 1, lOxTaq buffer 2.5 ⁇ 1, ⁇ 0.5 ⁇ 1, F primer 0.5 ⁇ 1, R primer 0.5 ⁇ 1 , Syber Green I ⁇ , ⁇ 2 ⁇ 1; PCR
- the reaction conditions were as follows: 94 ° C for 2 minutes, 94 ° C for 15 seconds, and 60 ° C for 30 seconds for 40 cycles.
- GAPDH was set as the internal reference gene, and the small interfering nucleic acid inhibitory activity was calculated according to the following formula. The results are shown in Table 2. .
- Realtime PCR primers were used in three pairs, and primers for the C gene, X gene, S and P genes were selected according to the small interfering nucleic acid samples.
- the sequence is as follows:
- Small interfering nucleic acid inhibitory activity [1- (copy number of hepatitis B virus gene after small interfering nucleic acid transfection / copy number of GAPDH after transfection of small interfering nucleic acid) I (copy number of control hepatitis B virus gene / Control well GAPDH copy number) ] ⁇ %.
- GAPDH glyceraldehyde-3-phosphate dehydrogenase gene.
- 3-Polyglycine glyceraldehyde dehydrogenase gene is a housekeeping gene in cells, which is stably expressed in cells and is not affected by other external factors, and thus serves as an internal reference for fluorescence quantitative PCR reactions.
- HBV-PS1 to HBV-PS2 and HBV-C1 to HBV-C2 provided by the present invention are capable of inhibiting B.
- HBV-PS1 3 ⁇ 4 HBV-C1 inhibition rate is above 80%.
- HBsAg hepatitis B virus s antigen
- HBeAg hepatitis B virus s antigen
- HepG2.2.15 cells were seeded at a density of 1 ⁇ 10 5 cells/well in 24-well cell culture plates using MEM complete medium containing 10% fetal bovine serum, 2 mM L-glutamine, 380 ug/ml G418 (from Beijing) University People's Hospital), cultured in an incubator with a temperature of 37 ° C and a C02 content of 5%, and passaged and replaced fresh medium every 72 hours.
- cells were digested with 0.25% trypsin, counted, and then seeded into 24-well plates at a concentration of 1 x 10 5 cells/ml, 1 ml per well.
- the small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2, and HBV-C1 to HBV-C2 obtained in Example 1 were obtained using Invitrogen's LipofectamineTM 2000 liposome. Transfection was performed separately without adding small interfering nucleic acids as a blank control.
- the specific steps are as follows: Dissolve the small interfering nucleic acid in RNase-free sterile water to prepare a small interfering nucleic acid solution with a concentration of 2 (mol/L. Aspirate the supernatant from each well, add 0.5 ml of OptiMEM I low. Serum medium (Invitrogen, 31985-062). Dilute 3 ⁇ 1 small interfering nucleic acid solution (20 ⁇ 1/ ⁇ in 50 ⁇ 1 Opti-MEM I low serum medium (Invitrogen, 31985-062), respectively.
- LipofectamineTM The 2000 liposome was diluted in 50 ⁇ l Opti-MEM I low serum medium (Invitrogen, 31985 ⁇ 62), and then the above two solutions were incubated at room temperature for 5 minutes, mixed, and the mixed solution was allowed to stand at room temperature for 20 minutes, and then ⁇ The mixed solution was added to the 24-well plate inoculated with cells, and gently shaken. The final concentration of the small interfering nucleic acid was 100 ⁇ . The cells were cultured at 37 ° C for 4 hours, and then 1 ml of 10% fetal bovine serum, 2 mM was added. L-Glutamine, 100 U/ml penicillin, 10 ( ⁇ g/ml streptomycin in MEM complete medium, and then cultured for an additional 48 hours.
- the amount of HBsAg in the collected cell supernatants was determined using an ELISA kit.
- the kit was purchased from Shanghai Kehua Biotechnology, and the operation was carried out according to the instructions.
- the light absorption value is the difference obtained by measuring the absorbance of the sample at 450 nm minus the absorbance of the sample at 630 nm.
- Inhibition rate (%) (P/N value of blank control well - P/N value of experimental well) / (P/N value of blank control well - 2.1) X 100%, knot As shown in Table 3.
- the amount of HBeAg in the collected cell supernatants was determined using an ELISA kit.
- the kit was purchased from Shanghai Kehua Biotechnology, and the operation was carried out according to the instructions.
- the light absorption value is the difference obtained by measuring the absorbance of the sample at 450 nm minus the absorbance of the sample at 630 nm.
- Inhibition rate (%) (blank control well P/N value - experimental well P/N value) / (blank control well P/N value -2.1) x l00%, and the results are shown in Table 4.
- Table 3 (blank control well P/N value - experimental well P/N value) / (blank control well P/N value -2.1) x l00%, and the results are shown in Table 4.
- the small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2, and HBV-C1 to HBV-C2 provided by the present invention are capable of inhibiting B.
- the expression of hepatitis B virus S antigen; especially the small interference nucleic acid HBV-X1, HBV-X3 HBV-PS1 and small interfering nucleic acid HBV ⁇ C1 inhibition rate are above 85%.
- HBV-PS1 to HBV-PS2 and HBV-C1 to HBV-C2 provided by the present invention are capable of inhibiting B.
- the expression of hepatitis E virus E antigen; especially HBV-X1, HBV-X3, HBV-PSl and HBV-Cl inhibition rate are above 65%.
- mice C57BL/6j-TgN (AlblHBV) 44Bri Hepatitis B virus gene mouse, male, 7-8 weeks old, 20-25 g, purchased from Department of Laboratory Animal Science, Peking University Medical School; Animal License No.: SCXK (Beijing) 2006-0008; Feeding conditions are carried out in accordance with SFP class animal standards.
- the small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2, and HBV-C1 to HBV-C2 obtained in Example 1 were chemically modified, respectively, wherein the chemical modification was U, C and G nucleotide pentoses of the sense strands of small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2, HBV-PS1 to HBV-PS2 and HBV-C1 to HBV-C2
- the 2'-OH was subjected to 2'-fluoro modification, and the 2'-OH of the antisense strand U and C nucleotide pentose was subjected to 2'-oxymethyl modification.
- the modified small interfering nucleic acid 1.2mg (0.09 ⁇ 1) was dissolved in 1.5ml RNase-free sterile physiological saline to prepare a small interference nucleic acid solution with a concentration of 6 ( ⁇ mol/L, and liposome).
- the mixture was mixed at a volume ratio of 1:1.
- the small interfering nucleic acid encapsulated with the liposome was added to 5 ml of RNase-free sterile physiological saline (small interfering nucleic acid concentration: 0.25 mg/ml) to obtain an injection solution.
- mice were injected with a conventional tail vein injection using an injection solution in an injection volume of 20 ml/kg body weight, and the blank control group was injected with the same volume of physiological saline, and only one injection.
- MAIN OUTCOME MEASURES On the 3rd, 5th, and 7th day after injection, the blood was taken from the eyelids, and the serum was obtained by routine centrifugation. The test was performed at -20 °C, and the mice were sacrificed after taking the eyeball 7 days after the administration. The liver tissue was taken by laparotomy on an ice box and homogenized for examination.
- HBV-C2 246 mmol/L
- the present invention provides small interfering nucleic acids HBV-X1 to HBV-X4, HBV-P1 to HBV-P2.
- HBV-PS1 to HBV-PS2 and HBV-C1 to HBV-C2 can reduce the content of ALT (alanine aminotransferase) in serum, among which HBV-X1, HBV-X3, HBV-PSl and HBV-Cl have the most obvious effects.
- the small interfering nucleic acids HBV-XI to HBV-X4, HBV-PI to HBV-P2, HBV-PS1 to HBV-PS2, and HBV-Cl to HBV-C2 provided by the present invention are capable of lowering serum.
- the light absorption value is the difference obtained by measuring the absorbance of the sample at 450 nm minus the absorbance of the sample at 630 nm.
- Inhibition rate (%) (blank control well P/N value - experimental well P/N value) / (blank control well P/N value - 2.1) X 100%, and the results are shown in Table 7.
- Table 7 Example Number of Small Interfering Nucleic Acid Numbers Inhibits HBsAg Content in Serum of Transgenic Mice
- the small interfering nucleic acids HBV-XI to HBV-X4 and HBV-PI provided by the present invention are:
- HBV-P2, HBV-PS1 to HBV-PS2, and HBV-C1 to HBV-C2 are all capable of inhibiting the amount of HBsAg in serum.
- HBV-X1, HBV-X3, HBV-PS1 and HBV 1 inhibited the serum HBsAg content by more than 75%.
- the liver was taken out, cut into tissue pieces of about 100 mg, and placed in a homogenizer for full grinding. Then, according to the instructions of Trizol (GIBCOL), using Trizol The total RNA extracted from the liver tissue was extracted by DNase digestion, and then reverse transcribed into cDNA. Then, the inhibitory effect of small interfering nucleic acid on the expression of hepatitis B virus mRNA was detected by real-time PCR.
- Trizol Trizol extracts total RNA.
- the mice were sacrificed by dislocation, and the liver tissue was taken by laparotomy on an ice box. About 100 mg of liver tissue was cut out, and 1 ml of Trizol reagent was added and homogenized with glass-Teflon or electric homogenizer. After homogenization, it was allowed to stand at room temperature for 30 min to ensure nuclear protein. The complex is completely separated.
- RNA purification 2 units of DNase I (RNase-free) (TakaRa) was added to total RNA and allowed to stand at 37 ° C for 30 min to remove residual DNA from total RNA; add equal volume of concentration to total RNA For 70% ethanol, shake and mix evenly; transfer the mixture to the purification column, centrifuge at 12000g for 15s at room temperature, discard the filtrate; add 700 ⁇ Wash Buffer I, centrifuge at 12000g for 15s at room temperature, discard the filtrate; add 500 ⁇ Wash Buffer II, Centrifuge at 12000g for 15s at room temperature, discard the filtrate; add 50 (L Wash Buffer II, centrifuge at room temperature 12000g for 15s, discard the filtrate; centrifuge lurin at room temperature 12000g, transfer the purification column to the RNA collection tube; add 30 ⁇ 1 DEPC water, room temperature Lrnin; centrifuge at 13000g for 2min at room temperature, discard the purification column and bring the RNA sample to -80 °C save.
- RNA reverse transcription The total RNA purified by 1 ⁇ ⁇ (2 L) was heated in EP tube at 70 ° C for 5 min; the EP tube was quickly placed on ice after centrifugation in a micro centrifuge; 25 mM MgCl 2 4 L, 10 ⁇ reverse transcription buffer was added in sequence.
- the obtained cDNA was used as a template for a PCR reaction, and a Real-time PCR reaction was carried out.
- the PCR kit was purchased from Beijing Meilaibo Medical Technology Co., Ltd.
- the Real-time PCR reaction system is: ddH 2 0 17.5 ⁇ 1, 10mM Dntp 0.5 ⁇ 1, lOxTaq buffer 2.5 ⁇ 1, Taq 0 ⁇ 5 ⁇ 1, F primer 0 ⁇ 5 ⁇ 1, R primer 0.5 ⁇ 1, Syber Green I ⁇ , ⁇ 2 ⁇ 1 ; PCR reaction
- the conditions were: 94 ° C for 2 minutes, 94 ° C for 15 seconds, and 60 ° C for 30 seconds for a total of 40 cycles.
- GAPDH was set as an internal reference, and the small interfering nucleic acid inhibitory activity was calculated according to the following formula. The results are shown in Table 8.
- Inhibitory activity of small interfering nucleic acids [1 - (copy of hepatitis B virus gene in the drug-administered group / copy number of GAPDH in the drug-administered group) I (copy number of hepatitis B virus gene in blank control group / copy number of GAPDH in blank control group)] ⁇ 100%.
- HBV-PS1 to HBV-PS2 and HBV-C1 to HBV-C2 were able to inhibit the expression of HBV gene in the liver of transgenic mice.
- HBV-X1, HBV-X3, HBV-PS1 and HBV-Cl inhibited the expression of HBV gene in the liver by more than 70%.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200980126405.7A CN102083983B (zh) | 2008-08-01 | 2009-08-03 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810135385.7 | 2008-08-01 | ||
CN200810135385 | 2008-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010012244A1 true WO2010012244A1 (zh) | 2010-02-04 |
Family
ID=41609976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/073049 WO2010012244A1 (zh) | 2008-08-01 | 2009-08-03 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102083983B (zh) |
WO (1) | WO2010012244A1 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014094645A1 (zh) * | 2012-12-21 | 2014-06-26 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
CN104031917A (zh) * | 2013-03-06 | 2014-09-10 | 石药集团中奇制药技术(石家庄)有限公司 | 一种针对HBx的siRNA及其脂质体制剂 |
US9034841B2 (en) | 2011-04-21 | 2015-05-19 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
CN105368860A (zh) * | 2014-08-29 | 2016-03-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种重组质粒载体及其构建方法和应用 |
WO2019128611A1 (en) * | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
WO2020038377A1 (zh) * | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
WO2020063198A1 (zh) * | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
WO2021037205A1 (zh) * | 2019-08-29 | 2021-03-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
RU2795400C2 (ru) * | 2017-12-29 | 2023-05-03 | Сучжоу Рибо Лайф Сайенс Ко., Лтд | Конъюгаты и их получение и применение |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2624045C2 (ru) * | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
CN106636086A (zh) * | 2015-10-30 | 2017-05-10 | 江苏命码生物科技有限公司 | 一种干扰乙肝病毒复制的siRNA、其构建方法及应用 |
CN112390835A (zh) * | 2019-08-14 | 2021-02-23 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
CN1289681C (zh) * | 2003-02-20 | 2006-12-13 | 重庆医科大学 | 乙型肝炎病毒siRNA表达载体的构建以及抗病毒治疗应用 |
CN1322898C (zh) * | 2003-06-17 | 2007-06-27 | 杭州新瑞佳生物医药技术开发有限公司 | 攻击人类乙型肝炎病毒的小干扰RNA分子(SiRNA)及其应用 |
CN100351376C (zh) * | 2004-12-30 | 2007-11-28 | 中山大学 | Hbv的rna干扰靶点序列及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1276086C (zh) * | 2003-08-13 | 2006-09-20 | 复旦大学 | 一类双链rna分子及其在制备抑制乙型肝炎病毒复制药物中的应用 |
CN1312283C (zh) * | 2004-12-07 | 2007-04-25 | 浙江大学 | 乙肝病毒基因的小干扰核糖核酸序列及制备方法 |
-
2009
- 2009-08-03 WO PCT/CN2009/073049 patent/WO2010012244A1/zh active Application Filing
- 2009-08-03 CN CN200980126405.7A patent/CN102083983B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
CN1289681C (zh) * | 2003-02-20 | 2006-12-13 | 重庆医科大学 | 乙型肝炎病毒siRNA表达载体的构建以及抗病毒治疗应用 |
CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
CN1322898C (zh) * | 2003-06-17 | 2007-06-27 | 杭州新瑞佳生物医药技术开发有限公司 | 攻击人类乙型肝炎病毒的小干扰RNA分子(SiRNA)及其应用 |
CN100351376C (zh) * | 2004-12-30 | 2007-11-28 | 中山大学 | Hbv的rna干扰靶点序列及其应用 |
Non-Patent Citations (2)
Title |
---|
YE JING JIA ET AL.: "Inhibition of hepatitis B virus by combined siRNAS in vitro", ACTA BIOLOGIAE EXPERIMENTALIS SINICA, vol. 38, no. 2, 30 April 2005 (2005-04-30) * |
ZHANG BING-QIANG ET AL.: "Inhibition ofHBV replication and antigen expression by RNA interference against different targets", CHIN J HEPATOL, vol. 14, no. 9, 30 September 2006 (2006-09-30) * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034841B2 (en) | 2011-04-21 | 2015-05-19 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
US9127278B2 (en) | 2011-04-21 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
US9677076B2 (en) | 2011-04-21 | 2017-06-13 | Ionis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
WO2014094645A1 (zh) * | 2012-12-21 | 2014-06-26 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
CN104031917A (zh) * | 2013-03-06 | 2014-09-10 | 石药集团中奇制药技术(石家庄)有限公司 | 一种针对HBx的siRNA及其脂质体制剂 |
CN105368860A (zh) * | 2014-08-29 | 2016-03-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种重组质粒载体及其构建方法和应用 |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
CN110959011B (zh) * | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
CN110959011A (zh) * | 2017-12-29 | 2020-04-03 | 苏州瑞博生物技术有限公司 | 缀合物及其制备方法和用途 |
WO2019128611A1 (en) * | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
RU2795400C2 (ru) * | 2017-12-29 | 2023-05-03 | Сучжоу Рибо Лайф Сайенс Ко., Лтд | Конъюгаты и их получение и применение |
EP3842534A4 (en) * | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF |
WO2020038377A1 (zh) * | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
EP3862024A4 (en) * | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF |
WO2020063198A1 (zh) * | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
WO2021037205A1 (zh) * | 2019-08-29 | 2021-03-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102083983B (zh) | 2014-04-16 |
CN102083983A (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010012244A1 (zh) | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 | |
AU2016296592B2 (en) | Compositions and agents against Hepatitis B virus and uses thereof | |
JP4709545B2 (ja) | 修飾された低分子干渉rna分子および使用方法 | |
CN116514890A (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
EP3472362A1 (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
TW201136594A (en) | Modulation of hsp47 expression | |
CN102140461B (zh) | 小干扰核酸和药物组合物及其制药应用 | |
EP1796732A2 (en) | Modified small interfering rna molecules and methods of use | |
WO2014094645A1 (zh) | 治疗乙型病毒性肝炎的rna干扰制剂 | |
JP2021524277A (ja) | Rtel1発現の調節用のオリゴヌクレオチド | |
WO2021130270A1 (en) | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv | |
JP2023506540A (ja) | B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用 | |
JP2023509870A (ja) | Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ | |
JP2023538630A (ja) | B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用 | |
JP2023506546A (ja) | B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用 | |
WO2011038700A1 (zh) | Fam3b基因的抑制剂和抑制剂组合物及抑制方法以及抑制剂在制药中的应用 | |
CN112266912A (zh) | 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用 | |
JP2023506954A (ja) | B型肝炎ウイルス感染を処置するためのsaraf阻害剤の使用 | |
JP2023506550A (ja) | B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用 | |
JP2023506547A (ja) | B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用 | |
WO2023111210A1 (en) | Combination of oligonucleotides for modulating rtel1 and fubp1 | |
CN116790590A (zh) | 靶向乙肝病毒rna的反义寡核苷酸、对应嵌合分子及其应用 | |
Ely | Optimisation of Expressed RNA Interference Effecters for the Inhibition of Hepatitis B Virus Replication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980126405.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09802437 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, DATED 17.05.11 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09802437 Country of ref document: EP Kind code of ref document: A1 |